Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6.
Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference.
2025 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Monday, May 5
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

9 hours ago

• Yahoo

Want to Retire Rich? 3 TSX Stocks to Add to Your Portfolio Now

Written by Sneha Nahata at The Motley Fool Canada Investing in TSX stocks with the ability to deliver above-average returns can help build wealth over time and retire rich. However, when investing for long-term financial goals, consider diversifying your portfolio to add stability and spread risk. Against this background, here are three TSX stocks that could deliver above-average returns and support you to retire rich. Dollarama (TSX:DOL) is a top TSX stock for building wealth for retirement. This Canadian dollar store retail chain consistently performs well in all market conditions, thanks to its value-focused model, and generates above-average returns. By offering everyday essentials and seasonal goods at low fixed prices, Dollarama consistently attracts strong consumer demand. Moreover, its focus on geographic expansion boosts sales and market presence. In the first quarter of fiscal 2026, Dollarama reported an 8.2% year-over-year increase in sales to $1.5 billion, with same-store sales rising 4.9%. This growth was driven by more customer visits and higher average transaction sizes. The stock has already surged 37.1% this year and has delivered nearly 315% in capital gains over the past five years by growing at an above-average compound annual growth rate (CAGR) of 32.9% Additionally, Dollarama has been consistently increasing its dividend since 2011, returning higher cash to its shareholders. Its value pricing strategy, wide product range, partnerships with third-party online delivery platforms, strong supply chain, and expanding geographical footprint will likely drive its earnings, supporting its share price and future dividend payments. 5N Plus (TSX:VNP) is a small-cap stock trading under $10. It manufactures specialty semiconductors and performance materials. These advanced components are vital to booming sectors such as renewable energy and space solar technology, positioning the company to deliver significant long-term returns. Strong demand and its focus on improving margins are enabling 5N Plus to scale profitably. Over the past five years, the stock has delivered a 486.9% return, compounding annually at 42.41%. Its bismuth-based products are gaining traction, and enhanced manufacturing capabilities combined with a robust global supply chain strengthen its outlook. Furthermore, as the demand for ultra-high-purity materials continues to increase, particularly from non-Chinese sources, 5N Plus is emerging as a crucial supplier. Its strong customer relationships, growing global presence, and leadership in niche markets make it a compelling bet for investors seeking long-term growth. Investors planning to retire rich could consider adding Cameco (TSX:CCO) to their long-term portfolios. This leading company in the nuclear energy space provides fuel, technology, and services spanning the full reactor lifecycle. Moreover, its investment in Westinghouse Electric deepens its control over the entire nuclear value chain, positioning it well to deliver reliable, carbon-free energy. With global demand for electricity surging, driven by AI-driven data centers, electrification, and decarbonization efforts, nuclear power is witnessing solid demand, and Cameco is well-positioned to capitalize on it. Thanks to solid secular demand trends, Cameco stock has increased at a CAGR of 47.5% over the past five years, delivering a return of approximately 600%. Looking ahead, its efficient production, strong market presence, and long-term supply contracts offer stability and growth potential. Cameco's expansion plans and exploration projects add further upside. Overall, Cameco's long-term outlook remains solid, making it an attractive investment for investors aiming to retire rich. The post Want to Retire Rich? 3 TSX Stocks to Add to Your Portfolio Now appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Sneha Nahata has no position in any of the stocks mentioned. The Motley Fool recommends Cameco. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio

Business Wire

11 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Business Upturn

20 hours ago

• Business Upturn

LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025

By GlobeNewswire Published on June 21, 2025, 02:30 IST LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025 Vancouver, June 20, 2025 – Leading Edge Materials Corp. ('Leading Edge Materials' or the 'Company') (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces results for the fiscal period ending April 30, 2025. All references to dollar amounts in this release are in Canadian dollars. Highlights During and After the Quarter During the three months ended April 30, 2025: • On February 9, 2025, the Company provided an update on a Rapid Development Plan ('RDP') for Norra Kärr, to be in production in the shortest possible timeframe, supplying HREE-rich eudialyte concentrate and industrial mineral nepheline syenite. • The Company provided an update on the value creation options being considered for Woxna Graphite, on February 16, 2025, including a possible restart of operations, the production of high-quality flake graphite concentrate. • On March 23, 2025, the Company provided a progress update on Norra Kärr, in the context of the European Commission's ('EC') Joint White Paper for European Readiness 2030, highlighting the increasing geopolitical competition over critical raw materials ('CRMs') and the need for the EU and its member states to build strategic reserves of raw materials. • On March 25, 2025, the EU announced its first list of Strategic Projects under the Critical Raw Materials Act ('CRMA'); Norra Kärr was not included. The Company stated its plan to reapply in the next round of applications. • On April 23, 2025, the Company announced granting of stock options (the 'Options') to directors, officers and consultants of the Company to purchase an aggregate of 6,850,000 common shares (the 'Optioned Shares') of the Company, at exercise price of C$0.24 per Optioned Share, expiring on the date that is 5 years from the date of grant for directors and officers and three years from the date of grant for consultants. The Options will vest 33% on the date of the grant, 33% one year after the date of grant and 34% two years after the date of grant. The Options were issued pursuant to the terms of the Company's Option Plan. Results of Operations Three Months Ended April 30, 2025, Compared to Three Months Ended January 31, 2025 During the three months ended April 30, 2025 ('Q2 2025') the Company reported a net loss of $1,179,168 compared to a reported net loss of $669,216 for the three months ended January 31, 2025 ('Q1 2025'), an increase in loss by $509,952, the increase in loss mainly due to share based compensation expenses of $585,529 (Q1 2025 – $129,292) and foreign exchange loss of $117,063 (Q1 2025 – gain $1,690). Three Months Ended April 30, 2025, Compared to Three Months Ended April 30, 2024 During the three months ended April 30, 2025 ('2025 period'), the Company reported a net loss of $1,179,168 compared to a net loss of $859,529 for the three months ended April 30, 2024 ('2024 period'), an increase in loss of $319,639, the increase in loss mainly due to share based compensation expenses of $585,529 (Q2 2024 – $349,923) and foreign exchange loss of $117,063 (Q2 2024 – $5,754). Selected Financial Data The following selected financial information is derived from the unaudited condensed consolidated interim financial statements of the Company prepared in accordance with IFRS. Fiscal 2025 Fiscal 2024 Fiscal 2023 Three Months Ended April 30,2025 $ January 31,2025 $ October 31,2024 $ July 31,2024 $ April 30,2024 $ January 31,2024 $ October 31,2023(Restated) $ July 31,2023(Restated) $ Operations Expenses (1,070,402) (696,037) (97,209) (797,070) (863,745) (660,617) (457,890) (309,832) Other items (108,766) 26,821 (222,820) (25,168) 4,216 (25,311) 195,209 (8,442) Comprehensive profit/(loss) (1,179,168) (669,216) (320,029) (822,238) (859,529) (685,928) (262,681) (318,274) Basic Profit/(loss) per share (0.01) (0.00) (0.00) (0.00) (0.01) (0.00) (0.00) (0.00) Diluted profit/(loss) per share (0.01) (0.00) (0.00) (0.00) (0.01) (0.00) (0.00) (0.00) Financial Position Working capital 1,191,514 2,198,641 3,337,686 3,973,458 1,610,635 2,316,098 2,713,098 848,952 Total assets 28,361,774 28,480,311 29,343,716 28,454,783 24,991,481 26,003,943 25,512,111 23,588,662 Total non-current liabilities (6,009,933) (5,596,369) (5,641,854) (5,683,545) (5,101,289) (5,489,843) (4,670,790) (5,109,575) Financial Condition / Capital Resources During the three months ended April 30, 2025, the Company recorded a net loss of $1,179,168 and, as of April 30, 2025, the Company had an accumulated deficit of $51,201,042 and working capital of $1,191,514. The Company maintains its Woxna Graphite mine in a 'production-ready' basis while minimizing costs. The Company is also evaluating a potential restart of flake graphite concentrate production. The Company anticipates that it has sufficient funding to meet anticipated levels of corporate administration and overheads for the ensuing twelve months however, it will need additional capital to provide working capital and recommence operations at the Woxna Graphite, to fund future development of the Norra Kärr project or to complete exploration activities in Romania. There is no assurance such additional capital will be available to the Company on acceptable terms or at all. In the longer term the recoverability of the carrying value of the Company's long-lived assets is dependent upon the Company's ability to preserve its interest in the underlying mineral property interests, the discovery of economically recoverable reserves, the achievement of profitable operations and the ability of the Company to obtain financing to support its ongoing exploration programs and mining operations. Outlook Concerns about critical raw materials – security of supply, supply chain resilience and defence requirements – have been recurring themes at conferences attended by the Company in recent months, with HREEs and natural graphite frequently mentioned; geopolitical uncertainties continue, with more talk about the weaponization of global trade in rare earth elements. On June 17, 2025, the G7 Critical Minerals Action Plan was announced focused on 'diversifying the responsible production and supply of critical minerals, encouraging investments in critical mineral projects and local value creation, and promoting innovation' in the G7, and with partners beyond, working together and 'to swiftly protect our economic and national security''. Against this backdrop and calls for more action to match the intent of the CRMA, the Company's portfolio is well positioned. Woxna Graphite Mine The Company maintains the Woxna Graphite Mine in a production-ready state while minimizing holding costs. An internal study completed in early 2022 assessed the potential for restarting operations and upgrading the processing plant to produce high-quality flake graphite concentrate. Work is now underway to update this study, forming the basis of a business plan to support possible project financing, customer prepayments, and access to Swedish or EU public funding, and, in addition. Highlighting Sweden's role in CRMs and graphite's importance, Sweden's Energy, Business and Industry Minister Ebba Busch recently stated that 'Sweden has unique opportunities to be and remain a strong player in global mineral politics. We have the most sustainable mining industry in the world – ethically sustainable, environmentally sustainable, and with good working conditions. The graphite that [Talga Group] is planning to produce is a key material in battery manufacturing and the green transition to a fossil-fuel-free society.' Norra Kärr Heavy Rare Earth Element ('HREE') Project As part of its Pre-feasibility ('PFS') workstreams, the Company is developing a Rapid Development Plan ('RDP') for Norra Kärr to enable the earliest possible production of HREE-rich eudialyte concentrate and industrial mineral nepheline syenite. A phased, small-scale start is under consideration to allow early access to the deposit, initial sales of nepheline syenite, early cash flow, and stockpiling of eudialyte concentrate for future processing. This approach is designed to reduce both risk and environmental impacts. Testwork has now been completed on nepheline syenite and aegirine to determine their mineralogy, chemical composition, and leachate chemistry. The promising results are being used to determine possible market segments and specifications that can be achieved, potential demand and pricing, to be included in an updated PFS economic model for Norra Kärr. The Company envisages the PFS will be completed in Q1 2026. On 24 March 2025, the EU announced its first list of Strategic Projects under the Critical Raw Materials Act (CRMA); Norra Kärr was not included. The Company plans to reapply in the next round of applications having continued to make significant progress since the last application was submitted in August 2024. In recent months, the Company's application for a new Exploitation Concession ('Bearbetningskoncession') 25-year mining lease has been out for consultation with County Administrative Boards ('CAB') and municipalities. The Company understands that CAB opinions have been received by the Mining Inspectorate ('Bergsstaten'). The Company will have an opportunity to respond to opinions and comments. Bihor Sud Nickel-Cobalt Exploration Project Exploration activities at the Bihor Sud project have continued, supported by the hard work of the four new geologists who joined the team in January. Works have included underground mapping, diamond drilling, geophysics, core logging, and sampling. The Company's goal remains to define a large-scale, mineable mineral resource; in gallery G2, targeting promising Zinc-Lead-Copper-Silver mineralization. Results to date are encouraging and underscore the project's strong potential for a significant polymetallic discovery. Financial Information The report for three months ending July 31, 2025, is expected to be published on or about September 19, 2025. On behalf of the Board of Directors, Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at: [email protected] Follow usTwitter: Linkedin: About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden), and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information The information was submitted for publication through the agency of the contact person set out above, on June 20, 2025, at 2:30 PM Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol 'LEM', OTCQB under the symbol 'LEMIF' and Nasdaq First North Stockholm under the symbol 'LEMSE'. Svensk Kapitalmarknadsgranskning ('SKMG') is the Company's Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email [email protected] or by phone +46 (0)8 913 008. Reader Advisory This news release may contain statements which constitute 'forward-looking information', including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words 'may', 'would', 'could', 'will', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company's future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, changes in the Company's intended use of proceeds from the Private Placement, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release. Attachments LEM – News Release Financial Results – April 30, 2025 Financial Report Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.